A sophisticated correction for methemoglobin and hemosiderin did not substantially alter the clinical performance of APT and ssMT imaging at the first follow-up 4 to 6 weeks after the completion of radiotherapy in 34 participants with glioma. This evidence concerns the gene HBG2 and glioma.